David E. Stockett

463 total citations
9 papers, 393 citations indexed

About

David E. Stockett is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, David E. Stockett has authored 9 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Oncology and 1 paper in Genetics. Recurrent topics in David E. Stockett's work include Cancer therapeutics and mechanisms (4 papers), DNA Repair Mechanisms (3 papers) and Neutropenia and Cancer Infections (2 papers). David E. Stockett is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), DNA Repair Mechanisms (3 papers) and Neutropenia and Cancer Infections (2 papers). David E. Stockett collaborates with scholars based in United States, United Kingdom and Sweden. David E. Stockett's co-authors include Rachael E. Hawtin, Judith A. Fox, Michelle R. Arkin, Andrew Conroy, Ute Hoch, Duncan Walker, Jo Ann W. Byl, Nguyêñ Duy Tân, Neil Osheroff and Wenjin Yang and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncotarget.

In The Last Decade

David E. Stockett

9 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David E. Stockett United States	6	252	189	71	62	59	9	393
Tapan Bagui United States	10	370 1.5×	268 1.4×	32 0.5×	73 1.2×	44 0.7×	13	486
Cheryl Napier United States	8	304 1.2×	286 1.5×	68 1.0×	58 0.9×	22 0.4×	12	501
Lata Chauhan United States	8	313 1.2×	159 0.8×	50 0.7×	28 0.5×	116 2.0×	15	489
Lisa Polin United States	12	234 0.9×	111 0.6×	100 1.4×	42 0.7×	36 0.6×	19	392
Steven M. Schmid United States	11	194 0.8×	132 0.7×	64 0.9×	18 0.3×	27 0.5×	14	389
Jacob I. Contreras United States	10	344 1.4×	195 1.0×	124 1.7×	61 1.0×	80 1.4×	12	536
Nicola J. Sunter United Kingdom	7	438 1.7×	181 1.0×	30 0.4×	20 0.3×	46 0.8×	9	527
Alessandra Bearzatto Italy	13	302 1.2×	219 1.2×	41 0.6×	30 0.5×	19 0.3×	22	476
Gloria Bullock United States	11	377 1.5×	281 1.5×	19 0.3×	97 1.6×	97 1.6×	15	571
Ahmed S.A. Mady United States	9	341 1.4×	114 0.6×	81 1.1×	25 0.4×	23 0.4×	13	444

Countries citing papers authored by David E. Stockett

Since Specialization

Citations

This map shows the geographic impact of David E. Stockett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Stockett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Stockett more than expected).

Fields of papers citing papers by David E. Stockett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Stockett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Stockett. The network helps show where David E. Stockett may publish in the future.

Co-authorship network of co-authors of David E. Stockett

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Stockett. A scholar is included among the top collaborators of David E. Stockett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Stockett. David E. Stockett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hawtin, Rachael E., David E. Stockett, Jo Ann W. Byl, et al.. (2010). Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II. PLoS ONE. 5(4). e10186–e10186. 127 indexed citations

Hawtin, Rachael E., David E. Stockett, Oi Kwan Wong, et al.. (2010). Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget. 1(7). 606–619. 36 indexed citations

Hawtin, Rachael E., David E. Stockett, Cecilia Lundin, Thomas Helleday, & Judith A. Fox. (2009). Abstract #1708: Voreloxin is active in breast cancer biopsies and potency is enhanced in a BRCA2 mutant background. Cancer Research. 69. 1708–1708. 1 indexed citations

Conroy, Andrew, David E. Stockett, Duncan Walker, et al.. (2009). SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemotherapy and Pharmacology. 64(4). 723–732. 106 indexed citations

Stockett, David E., et al.. (2009). Abstract C222: Voreloxin is synergistic in in vitro combination with cytarabine and additive in combination with azacitidine, decitabine, and clofarabine. Molecular Cancer Therapeutics. 8(12_Supplement). C222–C222. 1 indexed citations

Belmont, Brian J., Marc Evanchik, W. Michael Flanagan, et al.. (2009). SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemotherapy and Pharmacology. 65(4). 707–717. 53 indexed citations

Choong, Ingrid, Iana M. Serafimova, David E. Stockett, et al.. (2008). A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorganic & Medicinal Chemistry Letters. 18(21). 5763–5765. 10 indexed citations

Fahr, Bruce J., David E. Stockett, Sravanthi Cheeti, et al.. (2008). Modifications of the isonipecotic acid fragment of SNS-032: Analogs with improved permeability and lower efflux ratio. Bioorganic & Medicinal Chemistry Letters. 18(23). 6236–6239. 5 indexed citations

Bhaskar, Vinay, Debbie A. Law, Robert B. DuBridge, et al.. (2003). E-selectin up-regulation allows for targeted drug delivery in prostate cancer.. PubMed. 63(19). 6387–94. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact